Cambrex to be acquired by the Permira funds

7 Aug 2019

The CDMO's shareholders will receive $60.00 per share in cash.

Cambrex has signed a definitive agreement to be acquired by an affiliate of the Permira funds in a transaction valued at approximately $2.4 billion, including Cambrex’s net debt. Under the terms of the merger agreement, Cambrex shareholders will receive $60.00 in cash for each share of Cambrex common stock, which represents a 47.1% premium to the August 6 closing stock price and a 37.3% premium to the 60-day volume weighted average closing price leading up to this announcement.

Cambrex to be acquired by the Permira funds

Cambrex has grown to become a premier CDMO in the small molecule space over the last several years. The recent acquisitions of Halo Pharma in 2018 and Avista Pharma Solutions in 2019 added drug product manufacturing and a full range of early-stage and analytical testing services to the company’s leading position in drug substance manufacturing, allowing Cambrex to broaden customer relationships over the full product lifecycle, from pre-clinical through commercial.

“We are excited to announce this transaction with Permira, a global private equity firm that has made significant investments in the pharma services space. This agreement is a strong endorsement of our strategy and represents significant value for our shareholders,” commented Steve Klosk, President and CEO of Cambrex. “Cambrex will continue to invest aggressively in our commitment to our global customer base, where we are constantly looking at ways to provide the broadest possible range of world class services.”

“We are very excited to back Cambrex in its next phase of growth,” said Henry Minello, Principal in the Global Healthcare Group of Permira. “Over many years, Cambrex has built a leading position with best-in-class capabilities and facilities, backed by an excellent reputation for quality and technical expertise. We look forward to partnering with Cambrex’s talented management and employees to support the growth of its integrated services offering.”

Completion of the transaction is subject to customary closing conditions, including receipt of approval by Cambrex’s shareholders and customary regulatory approvals. Closing is expected to occur during the fourth quarter of 2019.

Read More

Related news

Funding to accelerate delivery of Univercells' vaccine portfolio

Funding to accelerate delivery of Univercells' vaccine portfolio

11 Oct 2019

European financing to support Univercells’ R&D investments to develop four essential and undersupplied global health vaccines to be produced at affordable prices, high quality and large volumes.

Read more 
Industrial-scale manufacture of therapeutic exosomes

Industrial-scale manufacture of therapeutic exosomes

10 Oct 2019

Coordinated purification process development service accelerates progress to clinical trials, and scale-up manufacturing.

Read more 
Janssen opens new biomanufacturing building in Ireland

Janssen opens new biomanufacturing building in Ireland

8 Oct 2019

Expansion creates 200 new full-time jobs and increases the company’s production capacity by an additional 19,100 m2.

Read more 
BASF and Biomillenia join forces in microbiome research to promote healthy skin

BASF and Biomillenia join forces in microbiome research to promote healthy skin

7 Oct 2019

Research aims to identify novel dermocosmetic active ingredients via unique microbiome-on-a-chip technology.

Read more 
Allergan expands Refresh eye treatment portfolio

Allergan expands Refresh eye treatment portfolio

7 Oct 2019

A trifecta of relief formulated with HydroCell technology offers new artificial tear options for patients suffering from eye dryness.

Read more 
BASF strengthens biotechnology footprint to enter natural F&F ingredients market

BASF strengthens biotechnology footprint to enter natural F&F ingredients market

3 Oct 2019

Market entrance with biotech-based natural vanillin, valencene and nootkatone.

Read more 
Unidose device approved for Tosymra sumatriptan spray

Unidose device approved for Tosymra sumatriptan spray

3 Oct 2019

Provides migraine sufferers with a convenient, patient-friendly delivery approach.

Read more 
One-stop-platform for plant-based nutraceuticals

One-stop-platform for plant-based nutraceuticals

2 Oct 2019

In 2020, nutra brands will look to ensure they have plant-based options across all product classes with many actively looking to move entire portfolios plant-based.

Read more 
BASF's new bioactive ingredient the wellness elixir for healthy skin

BASF's new bioactive ingredient the wellness elixir for healthy skin

1 Oct 2019

The active ingredient is a 100% natural extract from the chaga mushroom, obtained using an innovative eco-friendly technology: subcritical water extraction.

Read more 
Arctoris secures funding to advance novel robotic drug discovery platform

Arctoris secures funding to advance novel robotic drug discovery platform

1 Oct 2019

Platform will enable scientists and biotechnology entrepreneurs worldwide to make discoveries faster and more efficiently,

Read more